Dr. Juthamas Sukbuntherng
Head of Clinical Pharmacology & DMPK
Juthamas Sukbuntherng, Ph.D., is our Head of Clinical Pharmacology and DMPK, providing strategic leadership on preclinical and clinical development of our assets and pipelines. She has been involved in the early and late development of multiple approved drugs, such as sunitinib malate, gabapentin enacarbil and ibrutinib.
Dr. Sukbuntherng has nearly 25 years of experience in drug development, from discovery to clinical for various therapeutic areas in the biotechnology and pharmaceutical industries. In her latest role at Pharmacyclics, an AbbVie company, she successfully provided clinical pharmacology and DMPK support to the US and global approval of ibrutinib for the treatment of several oncology indications. In addition, she provided scientific leadership to cross-functional teams and led several discovery oncology projects.
Dr. Sukbuntherng started her career at Sugen in 1997, where she was involved in discovery of sunitinib malate. From 2003 to 2006, she was involved in the early development of several programs including FVIIa, CatS and HDAC at Celera Genomincs. She continued to expand her responsibility in the late development of gabapentin enacarbil at XenoPort , Inc. from 2006 to2011.
Dr. Sukbuntherng has published over 80 manuscripts and conference abstracts. Dr. Sukbuntherng received her Ph.D. in Pharmacokinetics from the University of Arizona.